Tissue-level evidence of fibroblast activation protein inhibitor imaging in hypertrophic obstructive cardiomyopathy: a case series-Reference-Cited by-同舟云学术

Tissue-level evidence of fibroblast activation protein inhibitor imaging in hypertrophic obstructive cardiomyopathy: a case series

Published:2024-04-15 Issue:5 Volume:8 Page:
ISSN:2514-2119
Container-title:European Heart Journal - Case Reports
language:en
Short-container-title:

Author:

Li Lina¹,Gao Jie²,Liu Xin³,Chen Bi-Xi¹,Su Pixiong²,Xie Boqia⁴^ORCID

Affiliation:

1. Department of Nuclear Medicine, Cardiovascular Imaging Center, Beijing Chaoyang Hospital, Capital Medical University , 8th Gongtinanlu Rd, 100020 Beijing , China

2. Department of Cardiac Surgery, Cardiovascular Imaging Center, Beijing Chaoyang Hospital, Capital Medical University , 8th Gongtinanlu Rd, 100020 Beijing , China

3. Department of Radiology, Cardiovascular Imaging Center, Beijing Chaoyang Hospital, Capital Medical University , 8th Gongtinanlu Rd, 100020 Beijing , China

4. Department of Cardiology, Cardiovascular Imaging Center, Beijing Chaoyang Hospital, Capital Medical University , 8th Gongtinanlu Rd, 100020 Beijing , China

Abstract

Abstract Background Myocardial fibrosis is a key pathological factor for the occurrence of ventricular arrhythmias in hypertrophic obstructive cardiomyopathy (HOCM). Case summary This case series reports on two patients diagnosed with HOCM who underwent 18F-fibroblast activation protein inhibitor (FAPI) positron-emission tomography/computed tomography imaging and Morrow myotomy procedure. The collected myocardial tissue was examined histopathologically. Both patients exhibited intense and heterogeneous 18F-FAPI uptake in the septum, with significant number of activated fibroblasts. Discussion Enhanced 18F-FAPI uptake was observed before irreversible fibrosis, and the degree of 18F-FAPI uptake was higher in tissue with greater fibrosis. 18F-FAPI imaging may provide a promising tool for guiding surgical strategy in HOCM, and further research is needed to fully explore its potential in clinical practice.

Funder

National Key Research and Development Program of China

Beijing Chaoyang Hospital

Capital Medical University Medical University

Beijing Municipal Science & Technology Commission

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ehjcr/advance-article-pdf/doi/10.1093/ehjcr/ytae189/57236803/ytae189.pdf

Reference15 articles.

1. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Ommen;Circulation,2020

2. Myocardial fibrosis predicts ventricular tachyarrhythmias;Disertori;Trends Cardiovasc Med,2017

3. Cardiac fibrosis;Frangogiannis;Cardiovasc Res,2021

4. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging;Xie;Eur J Nucl Med Mol Imaging,2022

5. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Ommen;Circulation,2020